249 related articles for article (PubMed ID: 28300852)
41. Ingenol mebutate for the treatment of actinic keratosis: effectiveness and safety in 246 patients treated in real-life clinical practice.
Ortega Del Olmo R; Salido-Vallejo R
J Dermatolog Treat; 2018 Jun; 29(4):393-399. PubMed ID: 28956675
[TBL] [Abstract][Full Text] [Related]
42. Ingenol mebutate: a new option for actinic keratosis treatment.
Gras J
Drugs Today (Barc); 2013 Jan; 49(1):15-22. PubMed ID: 23362492
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics of ingenol mebutate gel under maximum use conditions in large treatment areas.
Bucko AD; Jarratt M; Stough DB; Kyhl L; Villumsen J; Hall A
J Dermatolog Treat; 2018 Feb; 29(1):74-79. PubMed ID: 28524709
[TBL] [Abstract][Full Text] [Related]
44. [Bullous reaction after application of a single dose ingenol mebutate].
Salskov-Iversen ML; Lorentzen HF
Ugeskr Laeger; 2013 Dec; 175(49A):V07130437. PubMed ID: 25353257
[TBL] [Abstract][Full Text] [Related]
45. Analysis of apoptosis-associated molecules Erythroid differentiation regulator 1, bcl-2 and p53 in actinic keratosis after treatment with ingenol mebutate.
Woo YR; Lim JH; Jeong SW; Cho DH; Park HJ
Exp Dermatol; 2017 Nov; 26(11):1012-1017. PubMed ID: 28370377
[TBL] [Abstract][Full Text] [Related]
46. Effect of ingenol mebutate on actinic keratosis in a Korean population: A prospective clinical, dermoscopic and histopathological study from a single center.
Kim JS; Woo YR; Kim M; Park HJ
J Dermatol; 2018 Nov; 45(11):1324-1330. PubMed ID: 30260493
[TBL] [Abstract][Full Text] [Related]
47. Ingenol Mebutate: Expanded Utility.
Khalfe Y; Rosen T
J Drugs Dermatol; 2020 Feb 1 j; 19(2):156-161. PubMed ID: 32129959
[TBL] [Abstract][Full Text] [Related]
48. A randomized split-face clinical trial analyzing daylight photodynamic therapy with methyl aminolaevulinate vs ingenol mebutate gel for the treatment of multiple actinic keratoses of the face and the scalp.
Moggio E; Arisi M; Zane C; Calzavara-Pinton I; Calzavara-Pinton P
Photodiagnosis Photodyn Ther; 2016 Dec; 16():161-165. PubMed ID: 27530375
[TBL] [Abstract][Full Text] [Related]
49. PICATO (ingenol mebutate 0.015% and 0.05% gels): a novel treatment for actinic keratosis.
Abramovits W; Oquendo M; Vincent KD; Gupta AK
Skinmed; 2013; 11(2):111-5. PubMed ID: 23745230
[No Abstract] [Full Text] [Related]
50. Ingenol mebutate (Picato) for actinic keratosis.
Med Lett Drugs Ther; 2012 Apr; 54(1389):35-6. PubMed ID: 22538622
[No Abstract] [Full Text] [Related]
51. Efficacy of Ingenol Mebutate in the Treatment of Actinic Keratoses: A Pre- and Posttreatment Dermoscopic Comparative Analysis.
Carbotti M; Coppola R; Zanframundo S; Devirgiliis V; Panasiti V
Biomed Res Int; 2018; 2018():4381019. PubMed ID: 30246021
[TBL] [Abstract][Full Text] [Related]
52. A Randomized Split-Face Clinical Trial of Photodynamic Therapy with Methyl Aminolevulinate versus Ingenol Mebutate Gel for the Treatment of Multiple Actinic Keratoses of the Face and Scalp.
Zane C; Fabiano A; Arisi M; Calzavara-Pinton P
Dermatology; 2016; 232(4):472-7. PubMed ID: 27578305
[TBL] [Abstract][Full Text] [Related]
53. The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP).
Tzogani K; Nagercoil N; Hemmings RJ; Samir B; Gardette J; Demolis P; Salmonson T; Pignatti F
Eur J Dermatol; 2014; 24(4):457-63. PubMed ID: 25115145
[TBL] [Abstract][Full Text] [Related]
54. Ingenol mebutate as topical treatment for actinic keratosis based on a prospective, non-interventional, multicentre study of real-life clinical practice in Germany: efficacy and quality of life.
Diepgen TL; Eicke C; Bastian M
Eur J Dermatol; 2019 Aug; 29(4):401-408. PubMed ID: 31625920
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: a randomized, controlled 12-month study.
Garbe C; Basset-Seguin N; Poulin Y; Larsson T; Østerdal ML; Venkata R; Lear JT
Br J Dermatol; 2016 Mar; 174(3):505-13. PubMed ID: 26471889
[TBL] [Abstract][Full Text] [Related]
56. Clinical findings using ingenol mebutate gel to treat actinic keratoses.
Martin G; Swanson N
J Am Acad Dermatol; 2013 Jan; 68(1 Suppl 1):S39-48. PubMed ID: 23228305
[TBL] [Abstract][Full Text] [Related]
57. Quality of life in treatment of AK: Treatment burden of ingenol mebutate gel is small and short lasting.
Hanke WC; Norlin JM; Mark Knudsen K; Larsson T; Stone S
J Dermatolog Treat; 2016 Oct; 27(5):450-5. PubMed ID: 27052110
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of topical SR-T100 gel in treating actinic keratosis in Taiwan: A Phase III randomized double-blind vehicle-controlled parallel trial.
Yang CC; Wong TW; Lee CH; Hong CH; Chang CH; Lai FJ; Lin SH; Chi CC; Lin TK; Yen H; Wu CH; Sheu HM; Lan CE
J Dermatol Sci; 2018 Jun; 90(3):295-302. PubMed ID: 29530340
[TBL] [Abstract][Full Text] [Related]
59. Ingenol mebutate-mediated reduction in p53-positive keratinocytes in skin cancerization field directly correlates with clinical response in patients with multiple actinic keratoses.
Grandi V; di Gennaro P; Torrigiani S; Basco L; Lastrucci I; Pimpinelli N
J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1297-1303. PubMed ID: 30801837
[TBL] [Abstract][Full Text] [Related]
60. In-clinic application of ingenol mebutate 0.015% gel for actinic keratosis in large areas of the face is feasible and attracts a high rate of patient satisfaction: Results of a questionnaire.
Strydom F
Australas J Dermatol; 2018 Aug; 59(3):237-239. PubMed ID: 28776637
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
